154 related articles for article (PubMed ID: 29721715)
1. A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
Kommalapati A; Tella SH; Goyal G; Ganti AK; Krishnamurthy J; Tandra PK
Breast Cancer Res Treat; 2018 Aug; 170(3):677-685. PubMed ID: 29721715
[TBL] [Abstract][Full Text] [Related]
2. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?
Nguyen DH; Truong PT; Alexander C; Walter CV; Hayashi E; Christie J; Lesperance M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):39-45. PubMed ID: 22330986
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
5. Comparison of outcomes between women with de novo stage IV and relapsed breast cancer.
Kitagawa D; Horiguchi S; Yamashita T; Kuroi K; Shimizu K
J Nippon Med Sch; 2014; 81(3):139-47. PubMed ID: 24998960
[TBL] [Abstract][Full Text] [Related]
6. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
Hanrahan EO; Broglio KR; Buzdar AU; Theriault RL; Valero V; Cristofanilli M; Yin G; Kau SW; Hortobagyi GN; Rivera E
Cancer; 2005 Sep; 104(6):1158-71. PubMed ID: 16047352
[TBL] [Abstract][Full Text] [Related]
7. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
8. Survival differences among women with de novo stage IV and relapsed breast cancer.
Dawood S; Broglio K; Ensor J; Hortobagyi GN; Giordano SH
Ann Oncol; 2010 Nov; 21(11):2169-2174. PubMed ID: 20427349
[TBL] [Abstract][Full Text] [Related]
9. Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life.
Si Y; Yuan P; Hu N; Wang X; Ju J; Wang J; Ma F; Luo Y; Zhang P; Li Q; Xu B
Ann Surg Oncol; 2020 Apr; 27(4):1025-1033. PubMed ID: 31970572
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy.
Le Scodan R; Stevens D; Brain E; Floiras JL; Cohen-Solal C; De La Lande B; Tubiana-Hulin M; Yacoub S; Gutierrez M; Ali D; Gardner M; Moisson P; Villette S; Lerebours F; Munck JN; Labib A
J Clin Oncol; 2009 Mar; 27(9):1375-81. PubMed ID: 19204198
[TBL] [Abstract][Full Text] [Related]
11. Survival of de novo stage IV breast cancer patients over three decades.
Hölzel D; Eckel R; Bauerfeind I; Baier B; Beck T; Braun M; Ettl J; Hamann U; Harbeck N; Kiechle M; Mahner S; Schindlbeck C; de Waal J; Engel J
J Cancer Res Clin Oncol; 2017 Mar; 143(3):509-519. PubMed ID: 27853869
[TBL] [Abstract][Full Text] [Related]
12. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
Fouad TM; Kogawa T; Liu DD; Shen Y; Masuda H; El-Zein R; Woodward WA; Chavez-MacGregor M; Alvarez RH; Arun B; Lucci A; Krishnamurthy S; Babiera G; Buchholz TA; Valero V; Ueno NT
Breast Cancer Res Treat; 2015 Jul; 152(2):407-16. PubMed ID: 26017070
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
King TA; Lyman JP; Gonen M; Voci A; De Brot M; Boafo C; Sing AP; Hwang ES; Alvarado MD; Liu MC; Boughey JC; McGuire KP; Van Poznak CH; Jacobs LK; Meszoely IM; Krontiras H; Babiera GV; Norton L; Morrow M; Hudis CA
J Clin Oncol; 2016 Jul; 34(20):2359-65. PubMed ID: 27001590
[TBL] [Abstract][Full Text] [Related]
14. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.
Xing M; Sakaria S; Dhanasekaran R; Parekh S; Spivey J; Knechtle SJ; Zhang D; Kim HS
Cardiovasc Intervent Radiol; 2017 Mar; 40(3):410-420. PubMed ID: 27900445
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
16. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base.
Greif JM; Pezzi CM; Klimberg VS; Bailey L; Zuraek M
Ann Surg Oncol; 2012 Oct; 19(10):3199-204. PubMed ID: 22766989
[TBL] [Abstract][Full Text] [Related]
17. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
18. Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study.
Tan Y; Li X; Chen H; Hu Y; Jiang M; Fu J; Yuan Y; Ding K
Oncotarget; 2016 Oct; 7(43):70991-71000. PubMed ID: 27542240
[TBL] [Abstract][Full Text] [Related]
19. Role of Locoregional Treatment in De Novo Stage IV Breast Cancer.
Lee JS; Toktas O; Soran A
Clin Med Insights Oncol; 2020; 14():1179554920942440. PubMed ID: 32994701
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature.
Zeichner SB; Herna S; Mani A; Ambros T; Montero AJ; Mahtani RL; Ahn ER; Vogel CL
Breast Cancer Res Treat; 2015 Oct; 153(3):617-24. PubMed ID: 26358708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
